Adherium has developed the market-leading Smartinhaler platform that monitors usage of inhaled asthma and COPD medications and provides reminders and feedback that improve patient adherence. With an existing commercial relationship with AstraZeneca and strong relationships with other pharma companies and key opinion leaders through sales for clinical trials, Adherium is positioned for strong revenue growth. We value Adherium at A$188m, or A$1.31 per share.
20 Apr 2016
Smartinhaler improves medication adherence
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Smartinhaler improves medication adherence
Adherium Ltd. (ADR:ASX) | 0 0 5.9% | Mkt Cap: 15.7m
- Published:
20 Apr 2016 -
Author:
Dr Dennis Hulme -
Pages:
12
Adherium has developed the market-leading Smartinhaler platform that monitors usage of inhaled asthma and COPD medications and provides reminders and feedback that improve patient adherence. With an existing commercial relationship with AstraZeneca and strong relationships with other pharma companies and key opinion leaders through sales for clinical trials, Adherium is positioned for strong revenue growth. We value Adherium at A$188m, or A$1.31 per share.